Sun Pharmaceuticals (SUN) Acquires Organon & Co for $11.75 Billion
Published on · Source: bbc.com
AI Summary
Summarized by AI from the source belowSun Pharmaceuticals (SUN) announced an agreement to acquire Organon & Co for $11.75 billion, marking the largest overseas acquisition by an Indian company in nearly 20 years. This deal is part of a broader trend, with 162 Indian companies investing over $18 billion in outbound acquisitions in 2025, reflecting a 34% year-over-year increase. Notable acquisitions include Tata Motors' $4.4 billion purchase and IT firm Coforge's $2.35 billion acquisition. Analysts suggest that Indian firms are increasingly seeking overseas assets for strategic rather than merely symbolic reasons.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Organon & Co. (OGN)
Organon is a women’s-health-focused pharmaceutical company spun off from Merck.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier OGN news
- Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash
- Sun Pharma (SUN) Acquires Organon for $11.75 Billion
- Organon (OGN) Surges 39% on $12 Billion Merger Speculation
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
